Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MRPL28 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MRPL28 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for physical binding assays. |
View MRPL28 Products |
| Gene Delivery | MRPL28 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and mitochondrial translation assays. |
View MRPL28 Products |
| Benchmark Ab | Anti-MRPL28 Benchmark Antibody Recombinant positive control for western blot, IHC, and immunofluorescence. |
View MRPL28 Products |
| Validator | MRPL28 siRNA Set For knockdown verification and functional phenotypic assays. |
View MRPL28 Products |
| Related Target A | MRPL12 Mitochondrial ribosomal protein L12; crucial for mitochondrial translation and coordinate regulation with MRPL28. |
View MRPL12 Products |
| Related Target B | LRPPRC Leucine-rich pentatricopeptide repeat-containing protein; key regulator of mitochondrial gene expression and OXPHOS stability. |
View LRPPRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial matrix localization validation | Lentivirus-driven full-length ORF ensures correct intracellular targeting and processing. |
| Subfamily and ribosomal protein off-target screening | Highly purified homologous mitochondrial ribosomal proteins (MRPL panel) verified by mass spectrometry. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for target-specific knockdown rescue and validation. |
Live MRPL28 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MRPL28 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to small molecule inhibitors targeting mitochondrial translation and OXPHOS pathways. As first-generation therapies targeting cancer metabolism reach the clinic, the next wave of R&D is targeting MRPL28-driven chemoresistance in solid tumors, particularly in glioblastoma and ovarian cancers where mitochondrial biogenesis is highly upregulated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Medical Centers, Biotech Startups | Glioblastoma, Chemoresistant Solid Tumors | Target Engagement Assay (Need high-purity recombinant MRPL28 protein) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Metabolic Syndromes, Advanced Malignancies | In vitro Knockdown Validation (Need sequence-verified MRPL28 siRNA sets) |
| Gene Therapy / Overexpression | Mitochondrial Medicine Laboratories | Mitochondrial Myopathies, Metabolic Dysfunction | Stable Cell Line Generation (Need high-titer MRPL28 Lentivirus) |